Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an update.
Pharmaron Beijing Co., Ltd. has issued a supplemental announcement regarding the remuneration of its supervisors for the years 2019 to 2024. The company clarified that supervisors did not receive remuneration in their supervisory capacity but did receive compensation for other roles within the company. This announcement aims to correct previous disclosures and ensure compliance with the Hong Kong Stock Exchange’s listing rules, potentially impacting stakeholders’ understanding of the company’s governance and financial transparency.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and is involved in providing various pharmaceutical services and products.
Average Trading Volume: 8,275,847
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.13B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.